December 2007
Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p3
Trade Publication
The article reports on the positive interim results announced by BioLineRx Ltd. of an ongoing Phase 2 trial of BL-1020, a gamma-aminobutyric acid (GABA) enhanced antipsychotic. Morris C. Laster, MD, CEO of BioLineRx, said that these results from severely ill treatment resistant patients with psychosis are extremely encouraging, as they further substantiate existing preclinical and clinical data suggesting that BL-1020 possesses the efficacy of currently available antipsychotics but without their compliance limiting motor or metabolic side effects.


Related Articles

  • Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by positron emission tomography. Waddington, John L.; Waddington, J L // British Journal of Psychiatry;Apr89, Vol. 154, p433 

    The article discusses the imaging of neurotransmitter receptors in the brain of living schizophrenic patients by positron emission tomography (PET). A study from the Johns Hopkins PET group has found elevated density of caudate-putamen D-2 dopamine receptors in drug-naive schizophrenic patients....

  • BioLineRx to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p497 

    The article reports on the announcement of BioLineRx Ltd. on the release of data from the completed phase IIb trial of GABA-enhanced antipsychotic BL-1020 to be presented at the3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany. The trial has demonstrated the...

  • Computerised tomography in newly diagnosed schizophrenia and schizophreniform disorder. A controlled blind study. Rubin, Pia; Karle, Agnete; MøLler-Madsen, Susanne; Hertel, Charlotte; Povlsen, Uffe Juul; Noring, Ulla; Hemmingsen, Ralf; Rubin, P; Karle, A; Møller-Madsen, S; Hertel, C; Povlsen, U J; Noring, U; Hemmingsen, R // British Journal of Psychiatry;Nov93, Vol. 163, p604 

    Patients with newly diagnosed schizophrenia (n = 27) or schizophreniform disorder (n = 22) and 24 healthy volunteers were investigated by CT scan, the investigators being blind to subject status. The patients had never received medication or had been treated only briefly with neuroleptics. The...

  • BioLineRx's antipsychotic drug found effective in Phase IIa trial.  // PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p11 

    The article reports on the positive results shown in a Phase IIa trial of BioLineRX Ltd.'s BL-1020, a gamma-aminobutyric acid-enhanced antipsychotic. It showed statistically significant efficacy with no significant change in weight and no increase in extrapyramidal symptoms at study completion....

  • The use of high-dose antipsychotic medication. Thompson, C. // British Journal of Psychiatry;Apr94, Vol. 164, p448 

    The article focuses on views of a consensus panel of expert clinicians and pharmacologists regarding the use of high doses of antipsychotic drugs. Antipsychotics eliminate or reduce the intensity of psychotic experiences and have a calming effect. The therapeutic effect is related to the...

  • Metformin.  // Reactions Weekly;2/12/2011, Issue 1338, p25 

    The article describes a case of worsening psychosis in a 20-year-old woman who was receiving metformin for schizophrenia.

  • Movement Disorders in Elderly Users of Risperidone and First Generation Antipsychotic Agents: A Canadian Population-Based Study Vasilyeva, Irina; Biscontri, Robert G.; Enns, Murray W.; Metge, Colleen J.; Alessi-Severini, Silvia // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Despite concerns over the potential for severe adverse events, antipsychotic medications remain the mainstay of treatment of behaviour disorders and psychosis in elderly patients. Second-generation antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine) have generally...

  • Delusions of Parasitosis: A Dermatologist's Guide to Diagnosis and Treatment. Koo, John; Lee, Chai Sue // American Journal of Clinical Dermatology;Sep/Oct2001, Vol. 2 Issue 5, p285 

    Delusions of parasitosis is a rare psychiatric disorder in which the patient has a fixed, false belief that he or she is infested by parasites. Even though it is a psychiatric disorder, these patients usually present to a dermatologist because they are convinced that they have a dermatological...

  • Entacapone.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p129 

    The article presents a case study of a 64-year old man with Parkinson's disease (PD) who developed psychosis while receiving treatment of entacapone.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics